<code id='295692B250'></code><style id='295692B250'></style>
    • <acronym id='295692B250'></acronym>
      <center id='295692B250'><center id='295692B250'><tfoot id='295692B250'></tfoot></center><abbr id='295692B250'><dir id='295692B250'><tfoot id='295692B250'></tfoot><noframes id='295692B250'>

    • <optgroup id='295692B250'><strike id='295692B250'><sup id='295692B250'></sup></strike><code id='295692B250'></code></optgroup>
        1. <b id='295692B250'><label id='295692B250'><select id='295692B250'><dt id='295692B250'><span id='295692B250'></span></dt></select></label></b><u id='295692B250'></u>
          <i id='295692B250'><strike id='295692B250'><tt id='295692B250'><pre id='295692B250'></pre></tt></strike></i>

          fashion

          fashion

          author:explore    Page View:434
          George Yancopoulos on the 2024 Breakthrough Summit East stage.
          George Yancopoulos on the 2024 Breakthrough Summit East stage STAT

          George Yancopoulos is in touch with his teenage self.

          After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once-fledgling company into the $100 billion global drugmaker it is today. And you can trace a straight line back to the childhood fascination with science he fostered growing up in Woodside, Queens.

          advertisement

          “My high school science project was about regenerating neurons, and ‘Regeneron’ is a contraction of ‘regenerating neurons,’” Yancopoulos said at the STAT Summit East on Thursday. “In some ways I’m still working on my high school science project.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Experts study whether long Covid risk adds up with each reinfection
          Experts study whether long Covid risk adds up with each reinfection

          AstudyfromZiyadAl-Aly,clinicalepidemiologistatWashingtonUniversityinSt.Louis,showedthatvaccinationap

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Drug for rare kidney disease narrowly misses mark in clinical trial

          AdobeTravereTherapeuticssaidThursdaythatastudymeanttoconfirmthebenefitofitsnewlyapproveddrugforarare